You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma
  1. Shinichi Komiyama, MD, PhD*,†,‡,
  2. Yoshihiro Nishijima, MD, PhD§,
  3. Haruhiro Kondo, MD, PhD∥,
  4. Hiroyuki Nomura, MD, PhD,
  5. Satoshi Yamaguchi, MD, PhD#,
  6. Masayuki Futagami, MD, PhD**,
  7. Hiroharu Arai, MD, PhD†,‡,
  8. Yoshihito Yokoyama, MD, PhD**,
  9. Nao Suzuki, MD, PhD∥,
  10. Mikio Mikami, MD, PhD§,
  11. Kaneyuki Kubushiro, MD, PhD*,
  12. Daisuke Aoki, MD, PhD,
  13. Yasuhiro Udagawa, MD, PhD† and
  14. Ryuichiro Nishimura, MD, PhD#
  1. * Department of Gynecology, Toho University Ohashi Medical Center, Tokyo;
  2. † Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Aichi;
  3. ‡ Department of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama;
  4. § Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa;
  5. ∥ Department of Obstetrics and Gynecology, St Marianna University School of Medicine, Kawasaki;
  6. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo;
  7. # Department of Gynecologic Oncology, Hyogo Cancer Center, Hyogo;
  8. ** Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Aomori; and
  9. †† Department of Obstetrics and Gynecology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  1. Address correspondence and reprint requests to Shinichi Komiyama, MD, PhD, Department of Gynecology, Toho University Ohashi Medical Center, 2-17-6, Meguro-ku, 153–8515 Tokyo, Japan. E-mail: shinkomiyama{at}gmail.com.

Abstract

Objective We conducted a multicenter clinicopathological study to characterize patients with high-grade serous carcinoma presenting as primary peritoneal carcinoma (clinical PPC).

Methods At 9 sites in Japan, patients with clinical PPC diagnosed according to Gynecologic Oncology Group criteria were enrolled retrospectively. The Gynecologic Oncology Group criteria allow for minor ovarian involvement by high-grade serous carcinoma. There was no systematic detailed histopathological review of the fallopian tubes to determine whether they were involved by serous carcinoma.

Results There were 139 patients and 64% were aged 60 years or older. Median pretreatment serum CA-125 was 1653.5 IU/mL. Pretreatment performance status was poor in more than 50%, endometrial cytology was positive in 40.3%, and the preoperative clinical diagnosis was correct in 72.7%. Primary debulking surgery was performed in 36% of patients, whereas 64% underwent neoadjuvant chemotherapy (NAC) with interval debulking surgery (IDS). The main tumor sites were the upper abdomen (greater omentum), extrapelvic peritoneum, mesentery, and diaphragm. Lymph node metastasis was found in 46.8% of patients undergoing systematic retroperitoneal node dissection. The optimal surgery rate was 32.0% with primary debulking surgery versus 53.9% with NAC and IDS (P = 0.0139). The response rate was 82.0% with NAC and 80.6% with postoperative chemotherapy. Median progression-free survival was 19.0 months and median overall survival was 41.0 months. Multivariate analysis showed that prognostic factors for progression-free survival were NAC and residual tumor diameter after debulking surgery, whereas the only prognostic factor for overall survival was the residual tumor diameter.

Conclusions This study identified various characteristics of clinical PPC. Neoadjuvant chemotherapy with IDS is a reasonable treatment strategy, and complete debulking surgery is optimum.

  • Primary peritoneal carcinoma
  • Clinical diagnosis
  • High-grade serous carcinoma
  • Neoadjuvant chemotherapy
  • Interval debulking surgery
  • Prognostic factor

https://doi.org/10.1097/IGC.0000000000001167

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.